Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer

Inclusion Criteria: * Patients must have histologically and or cytologically confirmed metastatic colorectal cancer * Patients must have a wild type or mutated RAS tumor status known prior to enrollment * Metastatic colorectal cancer patients have progressed following at least one line of fluorouracil (5-FU)-based chemotherapy * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 * Patients must have measurable disease per irRECIST criteria for part 2 (dose expansion) * Absolute neutrophil count (ANC) \>= 1.0 x 10\^9/L (1,000/uL) * Platelet count \>= 75 x 10\^9/L (75000/L) * Hemoglobin \>= 8.0 g/dL (\>= 5.0 mmol/L) * Patients must be transfusion independent (i.e., no blood product transfusions for a period of at least 14 days prior to screening) * Serum creatinine \< 2 x upper limit of normal (ULN) or estimated creatinine clearance \> 30 ml/min as calculated using the method standard for the institution * Total serum bilirubin \< 1.5 x ULN, unless the patient has documented Gilbert syndrome * Aspartate and Alanine Aminotransferase (AST and ALT) \< 3 x ULN * Left ventricular ejection fraction (LVEF) that is greater than 40%, or the absence of New York Heart Association (NYHA) classification of greater than stage II congestive heart failure * Resolved acute effects of any prior therapy to baseline severity or grade =\< 2 Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 4.03 except for adverse events (AEs) not constituting a safety risk by …